OncoSec Medical Inc. (OTC:ONCS) said Thursday it will exhibit data from late stage studies on head and neck cancers at two upcoming conventions.
biomedical company, founded in 2011, develops advance-stage
ElectroOncology anti-cancer therapies to treat people with solid
OncoSec said data from its Phase IV study was chosen for
a poster session and oral presentation at the 5th European Conference
on Head and Neck Oncology, and takes place in Poland on April 18 through
Additionally, the data from a Phase III study will be
presented at the 8th International Head and Neck Cancer Conference in
Toronto on July 21 through 25, 2012.
The company has compiled and
analyzed data from both studies carried out in Europe and the United
States, since acquiring the OMS ElectroChemotherapy assets, in March
In a statement, OncoSec’s chief executive, Punit Dhillon, said: "With this data, we expect to finalize our clinical development
plan and move forward with commercializing the ElectroChemotherapy platform with a partner, either regionally or globally."
uses its electroporation delivery system which applies cell membrane
stimulation to deliver immunotherapy or chemotherapy to treat a range of
cancerous tumour types.
The OMS electroporation system has
proven to enhance cellular uptake, effectively treating cancerous cells
while sparing surrounding healthy tissue cutting through the toxic side
effects of current available treatment options like chemotherapy and
In 2011, the company managed to outline a clinical development plan for its local and potentially systemic ElectroImmunotherapy
program, which uses the OMS system to deliver a DNA-based immunotherapy, known as DNA IL-12.
IL-12 IS designed to induce a local immune response against the treated
cancerous tumour, while exploiting this response to initiate a global
systemic response against untreated tumours in other areas of the body.
For the metastatic melanoma trial, a total of up to 25 patients with stage three or four cutaneous and in-transit metastatic
melanoma will be enrolled in the phase two, single-arm, open-label and multi-centre study.